AFib & Liver Disease: Understanding the Connection & Risks

A growing body of evidence suggests a significant link between metabolic dysfunction-associated steatotic liver disease (MASLD) – a condition where excessive fat accumulates in the liver due to metabolic factors – and an increased long-term risk of developing atrial fibrillation (AFib), a common heart rhythm disorder. A recent meta-analysis, published in several journals including PubMed and Liver International, reinforces this association, adding to a growing understanding of the interconnectedness between liver health and cardiovascular wellbeing.

Understanding the Connection: MASLD and Atrial Fibrillation

Atrial fibrillation, or AFib, affects over 64 million people globally and is the most prevalent cardiac arrhythmia. It dramatically increases the risk of stroke, heart failure and other heart-related complications. MASLD, previously known as non-alcoholic fatty liver disease (NAFLD), is increasingly recognized as a systemic disease, meaning it doesn’t just affect the liver but impacts multiple organ systems. The new designation, MASLD, reflects a more precise understanding of the underlying metabolic drivers of the condition, moving away from simply excluding alcohol as a cause.

The recent meta-analysis examined data from 16 retrospective cohort studies, encompassing nearly 19.5 million individuals followed for a median of 7.2 years. Researchers found that individuals with MASLD had a 20% increased risk of developing AFib (hazard ratio 1.20, 95% CI 1.10-1.32). This finding remained statistically significant even after accounting for established cardiovascular risk factors like age, sex, body mass index, hypertension, and Type 2 diabetes. This suggests that MASLD contributes to AFib risk independently of these other factors.

What is MASLD? A Closer Look

MASLD is characterized by an accumulation of fat in the liver not caused by excessive alcohol consumption. It’s closely tied to metabolic syndrome, a cluster of conditions including obesity, insulin resistance, high blood pressure, and abnormal cholesterol levels. You’ll see different forms of steatotic liver disease, including MASLD with increased alcohol intake (MetALD) and alcoholic liver disease (ALD). Diagnosing MASLD can be done through liver biopsy, imaging techniques, or blood-based scores, though the optimal diagnostic approach is still evolving. The American Heart Association has also been investigating the impact of MASLD and MetALD on the risk of newly diagnosed AFib.

Severity of Liver Disease and AFib Risk

Interestingly, the meta-analysis did not find a clear correlation between the severity of liver fibrosis – the scarring of the liver – and an increased risk of AFib. While more severe liver disease is generally associated with worse health outcomes, the increased risk of AFib appeared to be present even in individuals with milder forms of MASLD. This suggests that the metabolic disturbances associated with MASLD, rather than the extent of liver damage itself, may be the primary driver of the increased AFib risk.

What the Study Doesn’t Tell Us

It’s crucial to understand that this meta-analysis demonstrates an association between MASLD and AFib, but it does not prove causation. While the data strongly suggest a link, it’s possible that other factors not accounted for in the analysis could be contributing to the observed relationship. The retrospective nature of the included studies also means that researchers were relying on existing data, which may be subject to biases or inaccuracies. For example, the diagnosis of MASLD and AFib relied on ICD codes, medical records, and electrocardiograms, which aren’t always perfectly accurate.

Who is Most Affected?

The increased risk of AFib associated with MASLD likely affects a substantial portion of the population, given the rising prevalence of both conditions. MASLD is estimated to affect a significant percentage of adults worldwide, particularly those with obesity and metabolic syndrome. The risk may be particularly pronounced in older adults, as both MASLD and AFib become more common with age. However, the meta-analysis included a diverse range of populations, suggesting that the association holds true across different demographic groups.

Implications for Clinical Practice and Public Health

These findings highlight the importance of considering liver health when assessing cardiovascular risk, particularly in individuals with metabolic syndrome or risk factors for MASLD. While there are currently no specific guidelines for screening for MASLD in individuals at risk of AFib, clinicians may want to consider evaluating liver function in patients with unexplained AFib or those with multiple cardiovascular risk factors. Further research is needed to determine whether interventions aimed at improving liver health, such as lifestyle modifications or pharmacological treatments, can reduce the risk of AFib.

The Role of Inflammation

One potential mechanism linking MASLD and AFib is chronic inflammation. MASLD is characterized by low-grade systemic inflammation, which can contribute to the development of various cardiovascular diseases, including AFib. Inflammation can disrupt the electrical signaling in the heart, making it more susceptible to arrhythmias. Further research is needed to investigate the role of inflammation in mediating the relationship between MASLD and AFib.

What Comes Next: Ongoing Research and Surveillance

The findings from this meta-analysis underscore the need for continued research to better understand the complex interplay between liver health and cardiovascular disease. Ongoing clinical trials are investigating the efficacy of various interventions for MASLD, including lifestyle modifications, pharmacological treatments, and bariatric surgery. Future studies should also focus on identifying individuals who are most vulnerable to the cardiovascular complications of MASLD and developing targeted prevention strategies. Public health surveillance systems should continue to monitor the prevalence of both MASLD and AFib to track trends and identify emerging risk factors. The scientific community is also actively working to refine diagnostic criteria for MASLD and develop more accurate methods for assessing liver fibrosis.